Bayer is deploying GenAI tools at scale while many corporates struggle to find ROI on AI. The difference may lie in a 12-year ...
Farming is changing, and Bayer Crop Sciences is right there, coming up with new ways to help farmers grow more food. It’s not ...
German conglomerate Bayer on Wednesday said it will sell a new soybean product called Intacta 5+ for farmers in Brazil, the ...
Berlin: Bayer has received accelerated approval from the U.S. Food and Drug Administration (FDA) for HYRNUO ...
Bayer’s Hyrnuo gets US FDA accelerated approval to treat patients with previously treated advanced HER2-mutant NSCLC: Berlin Friday, November 21, 2025, 11:00 Hrs [IST] Following ...
Zacks Investment Research on MSN
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
Regeneron Pharmaceuticals, Inc. REGN announced that the European Commission (EC) has approved label expansion of its PD-1 inhibitor Libtayo (cemiplimab). The EC approved Libtayo as an adjuvant ...
The FDA has given accelerated approval to Bayer for oral HER2 tyrosine kinase inhibitor sevabertinib as a second-line treatment for advanced HER2-mutant non-small cell lung cancer (NSCLC), allowing it ...
In 2024, the U.S. FDA granted HYRNUO Breakthrough Therapy designation for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, and ...
Bayer is reshaping its pharmaceutical business with a new operating model designed to enhance collaboration and bring research & development and commercialization closer together. In a recent episode ...
Bayer has cleared out four cancer candidates from its early-stage pipeline, including a STAT3 inhibitor acquired as part of its buyout of Vividion Therapeutics. The Vividion asset in question, called ...
Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results